Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 14/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.60 |
| ▸ | FABP4 | P15090 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31500236 | 0.91 | AKR1C3 (0.70) | GRIK1AKR1C3AKR1C2MAPTMEN1 | |
| SCHEMBL31060427 | 0.90 | AKR1C3 (0.72) | GRIK1AKR1C3AKR1C2GFERMEN1 | |
| SCHEMBL6551809 | 0.90 | AKR1C3 (0.72) | GRIK1AKR1C3AKR1C2GFERMEN1 | |
| SCHEMBL11603313 | 0.87 | GRIK1 (0.62) | GRIK1AKR1C3AKR1C2MEN1USP2 | |
| SCHEMBL28181761 | 0.87 | SIRT2 (0.54) | GRIK1MAPTGFERNGLY1MEN1 | |
| SCHEMBL847502 | 0.87 | GRIK1 (0.54) | GRIK1AKR1C3AKR1C2MAPTGFER | |
| SCHEMBL10834321 | 0.87 | GRIK1 (0.71) | GRIK1AKR1C3AKR1C2MAPTMEN1 | |
| SCHEMBL9537375 | 0.86 | MPO (0.68) | GRIK1AKR1C3AKR1C2MAPTGFER | |
| SCHEMBL14598921 | 0.86 | MAPT (0.65) | GRIK1AKR1C3AKR1C2MAPTGFER | |
| Lobenzarit SCHEMBL30753983 | 0.86 | GRIK1 (0.63) | GRIK1AKR1C3AKR1C2MAPTFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4996339-A | Colorless | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-26 | — | — | US | claimed |
| US-4921875-A | Use of amino-substituted benzoic acids as remedies for diarrhea, and medicaments based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-01 | — | — | US | claimed |
| US-4855208-A | Toner for developing electrostatic latent images | ORIENT CHEMICAL INDUSTRIES LTD. (JP) | 1989-08-08 | — | — | US | claimed |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-119528824-A | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4501912-A1 | NOVEL HETEROCYCLIC COMPOUND | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| CN-113166078-B | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-118475560-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-117417297-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-116924983-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-2012093861-A2 | ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE INCLUDING SAME | 주식회사 두산 (KR) | 2012-07-12 | — | — | WO | disclosed |
| WO-2012093861-A2 | ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE INCLUDING SAME | 주식회사 두산 (KR) | 2012-07-12 | — | — | WO | disclosed |
| EP-0298388-B1 | A toner for developing electrostatic latent images and a method of preparing the toner | ORIENT CHEMICAL IND (JP) | 1993-12-22 | — | — | EP | disclosed |
| EP-0471516-A1 | Tricyclic heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-19 | — | — | EP | disclosed |
| US-4996339-A | Colorless | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-26 | — | — | US | disclosed |
| US-4921875-A | Use of amino-substituted benzoic acids as remedies for diarrhea, and medicaments based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-01 | — | — | US | disclosed |
| US-4855208-A | Toner for developing electrostatic latent images | ORIENT CHEMICAL INDUSTRIES LTD. (JP) | 1989-08-08 | — | — | US | disclosed |
| EP-0298388-A2 | A toner for developing electrostatic latent images and a method of preparing the toner | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 1989-01-11 | — | — | EP | disclosed |
| US-4168312-A | Quinolone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | GRIK1 2458/4885AKR1C3 940/4885AKR1C2 371/4885 |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | GRIK1 2693/4885AKR1C3 2681/4885AKR1C2 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.